Skip to main content
TipRanks
Go Ultimate75% OFF

BioMarin Pharmaceutical (BMRN) Revenue by Segment

2,473 Followers

Revenue by Segment

In Q3 2026, BioMarin Pharmaceutical reported revenue by segment of $245.01M (Voxzogo), $107.82M (Naglazyme), $111.03M (Palynziq), $52.71M (Brineura), $56.60M (Aldurazyme) and $22.95M (Kuvan).

Breaks down revenue across different business units, highlighting which products or services drive the most sales and indicating areas of growth or potential risk.

$0.00$200.00M$400.00M$600.00M$800.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Voxzogo has emerged as BioMarin’s primary growth engine—a rapid commercial ramp since 2022 that now offsets the steady erosion in Kuvan, signaling successful commercialization but creating concentration risk around one newer product. Naglazyme and Palynziq are meaningful, rising contributors (Palynziq accelerating), while Brineura/Aldurazyme remain modestly steady and Roctavian/royalties are small and volatile. Key watcher for investors: sustainability of Voxzogo uptake, payor access and quarter-to-quarter volatility that could swing near-term results.

BMRN Revenue by Segment

PeriodVoxzogoNaglazymePalynziqBrineuraAldurazymeKuvanRoctavianFirdapseRoyalty and OtherGalafoldPombiliti + Opfolda
Q3 2026Sep 30, 2026$245.01M$107.82M$111.03M$52.71M$56.60M$22.95M$738.00K$0.00$11.57M$151.83M$48.59M
Q2 2026Jun 30, 2026$252.53M$135.25M$135.17M$51.37M$43.54M$24.44M$11.71M$0.00$5.32M$0.00$0.00
Q1 2026Mar 31, 2026$219.88M$130.07M$89.56M$47.10M$36.74M$23.88M$2.64M$0.00$6.13M$0.00$0.00
Q4 2025Dec 31, 2025$273.00M$120.00M$125.00M$49.00M$49.00M$23.00M$13.00M$0.00$15.24M$0.00$0.00
Q3 2025Sep 30, 2025$218.00M$122.00M$109.00M$48.00M$54.00M$24.00M$3.00M$0.00$15.32M$0.00$0.00
Q2 2025Jun 30, 2025$221.39M$128.87M$105.94M$48.69M$56.44M$27.03M$9.20M$0.00$12.43M$0.00$0.00
Q1 2025Mar 31, 2025$214.00M$114.00M$93.00M$40.00M$49.00M$25.00M$11.00M$0.00$10.50M$0.00$0.00
Q4 2024Dec 31, 2024$208.00M$110.00M$100.00M$48.00M$39.00M$28.00M$11.00M$0.00$11.68M$0.00$0.00
Q3 2024Sep 30, 2024$189.80M$131.90M$90.60M$37.00M$71.00M$28.10M$7.20M$0.00$11.90M$0.00$0.00
Q2 2024Jun 30, 2024$183.90M$132.00M$88.30M$45.30M$38.60M$28.60M$7.40M$0.00$9.90M$0.00$0.00
Q1 2024Mar 31, 2024$152.90M$105.60M$75.70M$39.00M$35.30M$35.90M$800.00K$0.00$11.00M$0.00$0.00
Q4 2023Dec 31, 2023$145.70M$98.30M$87.80M$43.60M$42.70M$36.70M$2.70M$0.00$13.10M$0.00$0.00
Q3 2023Sep 30, 2023$123.00M$108.90M$78.90M$41.00M$13.80M$42.90M$800.00K$0.00$13.10M$0.00$0.00
Q2 2023Jun 30, 2023$113.30M$90.10M$74.90M$38.10M$40.30M$50.60M$0.00$0.00$10.60M$0.00$0.00
Q1 2023Mar 31, 2023$87.80M$123.00M$62.40M$39.10M$34.40M$50.50M$0.00$0.00$10.00M$0.00$0.00
Q4 2022Dec 31, 2022$66.80M$100.50M$72.30M$42.60M$37.70M$53.60M$0.00$0.00$12.00M$0.00$0.00
Q3 2022Sep 30, 2022$48.30M$99.50M$66.20M$37.80M$29.00M$57.00M$0.00$0.00$12.00M$0.00$0.00
Q2 2022Jun 30, 2022$34.40M$115.80M$61.60M$37.70M$37.30M$57.60M$0.00$0.00$16.10M$0.00$0.00
Q1 2022Mar 31, 2022$19.70M$128.00M$54.90M$36.20M$24.40M$59.30M$0.00$0.00$13.80M$0.00$0.00
Q4 2021Dec 31, 2021$5.70M$83.10M$63.80M$37.40M$20.20M$68.50M$0.00$0.00$14.60M$0.00$0.00
Q3 2021Sep 30, 2021$100.00K$71.20M$60.70M$33.00M$24.40M$67.70M$0.00$0.00$14.90M$0.00$0.00
Q2 2021Jun 30, 2021$0.00$118.80M$58.90M$30.30M$28.10M$78.80M$0.00$0.00$15.00M$0.00$0.00
Q1 2021Mar 31, 2021$0.00$107.30M$54.00M$27.30M$50.00M$70.80M$0.00$0.00$18.30M$0.00$0.00
Q4 2020Dec 31, 2020$0.00$119.70M$49.60M$35.00M$1.20M$89.10M$0.00$0.00$15.10M$0.00$0.00
Q3 2020Sep 30, 2020$0.00$76.30M$46.10M$25.50M$41.00M$124.00M$0.00$0.00$16.00M$0.00$0.00
Q2 2020Jun 30, 2020$0.00$81.00M$40.60M$25.80M$32.30M$122.60M$0.00$0.00$10.50M$0.00$0.00
Q1 2020Mar 31, 2020$0.00$114.30M$34.60M$24.00M$55.70M$122.00M$0.00$1.30M$13.00M$0.00$0.00
Q4 2019Dec 31, 2019$0.00$94.90M$31.60M$25.20M$23.90M$122.60M$0.00$6.10M$17.90M$0.00$0.00

Related KPIs